Page 96 - SRPSKO DRUŠTVO ISTRAŽIVAČA RAKA

Serbian Association for Cancer Research SDIRSACR

L35

Palladium (II) Based-Anticancer Compounds: A New Hope or Not?

Engin Ulukaya 1

1Medical School of Istinye University, Department of Clinical Biochemistry, Istanbul, TURKEY

Cancer patients still need more effective chemotherapeutic/general cytotoxic drugs. Although target-based treatments
have become more common in recent years, chemotherapy is still necessary. Moreover, the combination of cytotoxic
and targeted therapy is expected to provide superior treatment options compared to chemotherapy alone. Synthesis
of new palladium (II) (Pd(II)) complexes provides a new arsenal in this regard. Therefore, the designation and creation
of new palladium (II)-based compounds are increasing. To date, many different compounds containing palladium (II)
as a metal have been synthesized and tested in terms of their cytotoxic activities against various tumor types. It seems
that the ligands attached to palladium (II) result in big differences in the cytotoxic potential of the complexes. In the
literature, varying ligands have already been used, such as pyrazoles, oxamate, triphenylphosphine, 2, 6-diacetylpyridine
bis (p-chlorophenylthiosemicarbazone, thioures, hydrazine, tetraaza [N 4], sulfur, thiosemicarbazones, hydrazine,
oxalato, proflavine, triazole, organoarsenic, and curcumin. All these new Pd(II)-based compounds yield different
cytotoxic potentials depending on the tumor types. Our group has broad experience with diverse metal complexes
including copper-based ones. Taken together, in this talk, novel Pd(II)-based compounds synthesized by other groups
will be discussed in comparison with our Pd(II)-based compounds in vitro and in vivo.
1-7

References:

1. Ulukaya E, Ari F, Dimas K, Ikitimur EI, Guney E, Yilmaz VT. Anti-cancer activity of a novel palladium(II) complex on
human breast cancer cells in vitro and in vivo. Eur J Med Chem. 2011 Oct;46(10):4957-63.
2. Ulukaya E, Frame FM, Cevatemre B, Pellacani D, Walker H, Mann VM, et al. Differential cytotoxic activity of a novel
palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells. PLoS
One. 2013 May 10;8(5):e64278.
3. Erkisa M, Ari F, Büyükköroğlu G, Şenel B, Yilmaz VT, Ulukaya E. Preparation and Characterization of Palladium
Derivate-Loaded Micelle Formulation in Vitro as an Innovative Therapy Option against Non-Small Cell Lung Cancer
Cells. Chem Biodivers. 2021 Sep;18(9):e2100402.
4. Cetin Y, Adiguzel Z, Polat HU, Akkoc T, Tas A, Cevatemre B, et al. A palladium(II)-saccharinate complex of terpyridine
exerts higher anticancer potency and less toxicity than cisplatin in a mouse allograft model. Anticancer Drugs. 2017
Sep;28(8):898-910.
5. Aydinlik S, Uvez A, Kiyan HT, Gurel-Gurevin E, Yilmaz VT, Ulukaya E, Armutak EI. Palladium (II) complex and
thalidomide intercept angiogenic signaling via targeting FAK/Src and Erk/Akt/PLCγ dependent autophagy pathways
in human umbilical vein endothelial cells. Microvasc Res. 2021 Nov;138:104229.
6. Genel ME, Adacan K, Selvi S, Kutucu DE, Uvez A, Armutak EI, et al. Apoptosis-inducing, anti-angiogenic and anti-
migratory effects of a dinuclear Pd(II) complex on breast cancer: A promising novel compound. Microvasc Res.
2024 Jan;151:104619.

81